It is one of the main causes of end-stage renal disease (ESRD) (Tang et al., 2019
This compound works by activating amylin receptors located in specific regions of the brain, particularly the area postrema and nucleus tractus solitarius of the brainstem [1]
The Science Behind the Controversial Peptide As interest in BPC-157 grows, experts warn that the science hasnt caught up with the hype
Volumes and concentrations reported come from published trial protocols, vendor reconstitution sheets, and self-reported community sources
The risk of systemic copper overload is negligible when used topically at recommended concentrations
Studies have demonstrated that agonists of these receptors reduce serum bilirubin and increase urinary excretion of glucuronidated products in cholestatic models [55,56,57]